These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 402011

  • 1. Altered receptor sensitivity following chronic drug administration in man: the tardive dyskinesia model [proceedings].
    Rubovits R.
    Psychopharmacol Bull; 1977 Jan; 13(1):49-50. PubMed ID: 402011
    [No Abstract] [Full Text] [Related]

  • 2. Neuroleptic dosage, duration, and tardive dyskinesia.
    Allen RE, Stimmel GL.
    Dis Nerv Syst; 1977 May; 38(5):385-7. PubMed ID: 852370
    [No Abstract] [Full Text] [Related]

  • 3. The pathophysiology of tardive dyskinesia.
    Klawans HL, Carvey P, Tanner CM, Goetz CG.
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Animal models of tardive dyskinesia--a review.
    Kulkarni SK, Naidu PS.
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH, Diamond BI.
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M, Friedhoff AJ, Diamond F.
    Adv Neurol; 1983 Apr; 37():253-8. PubMed ID: 6134444
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The pathophysiologic basis of tardive dyskinesia.
    Baldessarini RJ.
    Psychopharmacol Bull; 1978 Oct; 14(4):79-81. PubMed ID: 30114
    [No Abstract] [Full Text] [Related]

  • 15. Modulation of tardive dyskinesia by estrogen: neurochemical studies in an animal model.
    Gordon JH, Diamond BI.
    Trans Am Neurol Assoc; 1979 Oct; 104():97-100. PubMed ID: 553438
    [No Abstract] [Full Text] [Related]

  • 16. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL, Cross AJ, Gamble SJ, Bourne RC.
    Adv Biochem Psychopharmacol; 1983 Oct; 37():299-308. PubMed ID: 6138952
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tardive dyskinesia and changing concepts of antipsychotic drug use: a nursing prospective.
    Doller JC.
    J Psychiatr Nurs Ment Health Serv; 1977 Nov; 15(11):23-6. PubMed ID: 200748
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [What is the connection between Parkinson disease and tardive dyskinesia?].
    Gunne LM, Andrén PE.
    Lakartidningen; 1994 Aug 24; 91(34):2953-5. PubMed ID: 7990538
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.